Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
Not intended for U.S. and UK Media Berlin, August 28, 2022 – Bayer announced today the start of a Phase III clinical development program “OCEANIC” to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor, as a potential new treatment in patients with atrial fibrillation and in patients with a non-cardioembolic …